Regeneron CEO Says Fears Over Eylea ' Greatly Exaggerated ' Regeneron CEO Says Fears Over Eylea ' Greatly Exaggerated '

Fears of the demise of blockbuster eye drug Eylea (aflibercept) were"greatly exaggerated," Regeneron Pharmaceuticals Inc ' s chief executive said on Thursday, after the treatment and new eczema drug Dupixent (dupilumab) powered the company ' s fourth-quarter results.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Dermatology News Source Type: news